CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing investigational antibody therapeutics, based on its Probody® technology platform, for the treatment of cancer. Co.'s Probody therapeutic approach is designed to enable conditional activation of antibody-based drugs within cancer tissue to target the tumor microenvironment and minimize drug activity in healthy tissue and in circulation. Co.'s primary product candidate is CX-072, a Probody therapeutic targeting programmed cell death ligand 1, a validated immuno-oncology target. Co.'s second product candidate, CX-2009, is a Probody Drug Conjugate directed against CD166, a drug target. The CTMX stock yearly return is shown above.
The yearly return on the CTMX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CTMX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|